The 2012-21 forecast period will see the loss of exclusivity for the leading non-insulin antidiabetic Actos franchise, while new launches include the first once-weekly GLP-1 agonists and the oral SGLT-2 inhibitor class, to compete in an increasingly crowded treatment algorithm in type 2 diabetes.
We further extracted information on the concomitant use of antidiabetic drugs during the year 2012 using the Encuity Research Treatment Answers database. This database includes data from a survey of 3,200 office-based physicians representing 30 specialties across the U.S. who report on all patient activity during 1 typical workday per month.